Rafael Amado compensation by year
Allogene Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Salary | $145,833 | $510,000 | $571,591 | $633,627 |
| Bonus | $0 | $75,000 | $100,000 | $0 |
| Stock awards | $4,249,976 | $561,176 | $6,839,951 | $2,299,999 |
| Option awards | $2,759,623 | $1,262,643 | $1,963,489 | $2,299,553 |
| Non-equity incentive | $71,726 | $255,000 | $228,000 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $225,000 | $0 | $11,125 | $11,531 |
| Total | $7,452,158 | $2,663,819 | $9,714,156 | $5,244,710 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 24, 2023, accession 0001737287-23-000041, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001737287-23-000041. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2023.
Allogene Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| David Chang | President and Chief Executive Officer | $14,797,837 |
| Eric Schmidt | Chief Financial Officer | $5,279,677 |
| Alison Moore | Chief Technical Officer | $5,279,236 |
| Rafael Amado · this page | Former Executive Vice President of Research and Development | $5,244,710 |
| Veer Bhavnagri | Former General Counsel | $4,066,186 |
The full Allogene Therapeutics compensation record
free company briefThis page is one person within Allogene Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Allogene Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Allogene Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.